8-K: FOXO Technologies Approves Reverse Stock Split

FOXO Technologies' majority stockholder approved a reverse stock split with a ratio between 1:10 and 1:500, to be implemented by July 31, 2026.

Summary

• The majority stockholder, Rennova Health, Inc., which is controlled by FOXO Technologies Inc.'s CEO, approved a proposal to amend the Certificate of Incorporation.
• The amendment will effect a reverse stock split of the issued and outstanding Class A Common Stock.
• The reverse stock split ratio will range from one-for-ten (1:10) to one-for-five hundred (1:500).
• The exact ratio within this range will be determined at the sole discretion of the Company's Board of Directors.
• The reverse split can be effected any time before July 31, 2026.
• As of September 2, 2025, Rennova Health, Inc. held approximately 60% of the company's voting rights.
• The company will file a preliminary Information Statement on Schedule 14C (PRE 14C) with the SEC.
• A definitive Information Statement on Schedule 14C will be mailed to stockholders of record as of September 2, 2025.
• The approved actions will become effective 20 days after the mailing of the definitive Information Statement.

Sentiment

Score: 3

Explanation: The filing indicates a necessary corporate action (reverse stock split) to address a low share price, which is generally a negative signal about the company's market performance, despite being a procedural step to maintain listing compliance. It does not provide positive operational or financial news.

Positives

• Approval of a reverse stock split provides the company with a mechanism to potentially increase its share price, which can be crucial for maintaining stock exchange listing requirements.

Negatives

• The necessity for a reverse stock split, especially with a potential ratio up to 1:500, often indicates a significantly low share price, which can be a negative signal to investors.
• Reverse stock splits do not change the fundamental value of the company and can sometimes lead to further share price declines post-split due to negative market perception.

Risks

• Risk of delisting from a stock exchange if the share price does not meet minimum requirements, which the reverse split aims to address.
• Potential for continued share price decline even after the reverse split, as the split itself does not alter the company's underlying business fundamentals.
• Investor perception of a reverse split can be negative, potentially leading to reduced investor confidence and further selling pressure.

Future Outlook

The Board of Directors has been granted the discretion to determine the exact reverse stock split ratio, within the approved range of 1:10 to 1:500, and the timing of its implementation, which must occur before July 31, 2026. The company will proceed with filing a preliminary Information Statement on Schedule 14C, followed by mailing a definitive statement, with the approved actions becoming effective 20 days after the mailing.

Management Comments

• The exact ratio within such range [1:10 to 1:500] is to be determined at the sole discretion of the Company's Board of Directors.

Industry Context

Reverse stock splits are a common corporate action for companies whose stock price has fallen significantly, often below minimum exchange listing requirements (e.g., $1.00 per share for Nasdaq). This action is a standard strategy to regain compliance and potentially improve stock liquidity and investor perception, though it does not address underlying business performance or fundamental value.

Comparison to Industry Standards

• Reverse stock splits are a standard corporate action for companies facing low share prices, often to meet exchange listing requirements, similar to actions taken by companies like Sundial Growers (SNDL) or Ideanomics (IDEX) to maintain compliance with major exchanges.
• The wide range of the proposed split ratio (1:10 to 1:500) is not uncommon, providing the board flexibility to adjust based on market conditions and the company's stock price leading up to the implementation, a practice seen across various industries.
• The approval by written consent from a majority shareholder is a common and legally permissible method for corporate actions, especially when a single entity or a small group holds significant voting power, aligning with corporate governance practices in many publicly traded companies.

Corporate Governance

Related Party Transactions

• Rennova Health, Inc., the majority stockholder that approved the reverse stock split, is controlled by FOXO Technologies Inc.'s Chief Executive Officer.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares held, with a proportional increase in share price, but no immediate change in the total value of their holdings. The action aims to prevent delisting, which benefits shareholders by maintaining market access.
• The Board of Directors has been granted significant discretion to determine the exact ratio and timing of the reverse split, impacting their strategic decision-making.
• Management, particularly the CEO, has influenced this corporate action through control of the majority stockholder, highlighting the CEO's strategic role.

Next Steps

• File a preliminary Information Statement on Schedule 14C (PRE 14C) with the U.S. Securities and Exchange Commission.
• Mail the definitive Information Statement on Schedule 14C to stockholders of record as of September 2, 2025.
• The approved actions will become effective 20 days after the mailing of the definitive Information Statement.
• The Board of Directors will determine the exact reverse stock split ratio (between 1:10 and 1:500) and the timing of its implementation before July 31, 2026.

Key Dates

Recommendation

The approval of a reverse stock split is a procedural step often taken by companies with significantly low share prices to meet exchange listing requirements. While it addresses a critical compliance issue, it does not inherently improve the company's operational performance or financial health. The wide range of the split ratio (1:10 to 1:500) suggests a substantial need to increase the per-share price. Investors should hold to observe if the company can leverage this action to stabilize its market position and demonstrate fundamental business improvements, rather than viewing it as a catalyst for immediate growth. Further analysis of the company's financials and strategic initiatives is required before a more definitive recommendation.

Keywords

FOXO Technologies, reverse stock split, Class A Common Stock, SEC filing, 8-K, corporate governance, shareholder vote, Rennova Health, stock exchange compliance